Latest Pharma Insights
Finance Watch: A Pair Of Startups Launch With High-Profile Execs At The Helm
Private Company Edition: K2 Therapeutics emerges with $50m in seed funding and CEO Ying Huang, who recently vacated the CEO post at Legend Biotech. Boulevard Bio came out of stealth with $65m and former Sanofi CSO Frank Nestle as a co-founder and board member.
Scrip - August 12, 2026
Private Company Edition: K2 Therapeutics emerges with $50m in seed funding and CEO Ying Huang, who recently vacated the CEO post at Legend Biotech. Boulevard Bio came out of stealth with $65m and former Sanofi CSO Frank Nestle as a co-founder and board member.
Scrip - August 12, 2026
Former SpineFrontier CFO Sentenced To Four Months In Surgeon Kickback Scheme
The former CFO of spinal implant firm SpineFrontier Inc. will serve four months in prison for his role in paying sham consulting fees to surgeons who agreed to use the company’s products.
Medtech Insight - August 12, 2026
The former CFO of spinal implant firm SpineFrontier Inc. will serve four months in prison for his role in paying sham consulting fees to surgeons who agreed to use the company’s products.
Medtech Insight - August 12, 2026
Four Serious Injuries Linked to Class I Recall Of Hamilton Medical Ventilator Circuit Sets
Hamilton Medical is recalling certain coaxial breathing circuit sets after identifying a valve defect that can cause inadequate ventilation and oxygen desaturation. The Class I recall is associated with four serious injuries but no deaths and follows an early alert the agency posted in June.
Medtech Insight - August 12, 2026
Hamilton Medical is recalling certain coaxial breathing circuit sets after identifying a valve defect that can cause inadequate ventilation and oxygen desaturation. The Class I recall is associated with four serious injuries but no deaths and follows an early alert the agency posted in June.
Medtech Insight - August 12, 2026
Methyl-Life Founder Turned From Health Crisis To Personalized Nutrients Targeting Genetic Factors
Jamie Hope discovered her chronic illness with symptoms including crippling fatigue, debilitating headaches, extreme muscle stiffness and pain, belly pain and low mood, was linked to genetic factors requiring specialized nutrients.
HBW Insight - August 12, 2026
Jamie Hope discovered her chronic illness with symptoms including crippling fatigue, debilitating headaches, extreme muscle stiffness and pain, belly pain and low mood, was linked to genetic factors requiring specialized nutrients.
HBW Insight - August 12, 2026
Reckitt’s Mucinex 12HR Cold & Fever Approved On Additional Evidence Supporting Naproxen Dosing
Reckitt launching Mucinex 12HR Cold & Fever Multi-Symptom following FDA approval in December 2025 and after it responded to complete response letter with additional evidence supporting combining naproxen with guaifenesin and dextromethorphan used in Mucinex DM.
HBW Insight - August 12, 2026
Reckitt launching Mucinex 12HR Cold & Fever Multi-Symptom following FDA approval in December 2025 and after it responded to complete response letter with additional evidence supporting combining naproxen with guaifenesin and dextromethorphan used in Mucinex DM.
HBW Insight - August 12, 2026
In Brief: Lilly Goes Into Battle To Defend Retatrutide From Illegal Sellers
The Indianapolis drugmaker filed six lawsuits against companies selling versions of the drug and asked the service providers they depend on to step up as well.
Scrip - August 12, 2026
The Indianapolis drugmaker filed six lawsuits against companies selling versions of the drug and asked the service providers they depend on to step up as well.
Scrip - August 12, 2026
Definium Riding High On Psychedelic Success In GAD
The company reported positive Phase III data for DT120 in generalized anxiety disorder, an area that has not seen a new drug approved in nearly 20 years.
Scrip - August 12, 2026
The company reported positive Phase III data for DT120 in generalized anxiety disorder, an area that has not seen a new drug approved in nearly 20 years.
Scrip - August 12, 2026
In Brief: US Preferred For First-In-Human Trials, But Obstacles Send Sponsors Abroad
A new survey by MassBio and BCAI found that US FDA practices are making countries like China and Australia more attractive, though the FDA has already begun to respond.
Scrip - August 12, 2026
A new survey by MassBio and BCAI found that US FDA practices are making countries like China and Australia more attractive, though the FDA has already begun to respond.
Scrip - August 12, 2026
ITM Setback Highlights Challenges Of Making Radiopharmaceuticals
The German firm has received a complete response letter from the US FDA for its GEP-NET product due to manufacturing issues but remains confident of approval.
Scrip - August 12, 2026
The German firm has received a complete response letter from the US FDA for its GEP-NET product due to manufacturing issues but remains confident of approval.
Scrip - August 12, 2026
Speed to Scale: How India’s Pharma Market Is Minting Billion-Rupee Brands
More pharma brands in India ranging from in-licensed Chinese cancer therapies to cough and cold medications are crossing the INR100 crore sales threshold, with some doing so faster than ever before. Experts discuss the trend and also what Mounjaro's extraordinary market entry reveals.
Scrip - August 12, 2026
More pharma brands in India ranging from in-licensed Chinese cancer therapies to cough and cold medications are crossing the INR100 crore sales threshold, with some doing so faster than ever before. Experts discuss the trend and also what Mounjaro's extraordinary market entry reveals.
Scrip - August 12, 2026
Alcon’s New-Product Wave Carries Q2 As It Walks Away From Accommodating IOL Bet
UNITY surgical systems, PanOptix Pro and a fast-ramping dry-eye franchise drove 7% constant-currency growth in the second quarter — even as Alcon took a $402m charge to discontinue its PowerVision accommodating lens programs and struck a light-adjustable IOL collaboration with RxSight.
Medtech Insight - August 12, 2026
UNITY surgical systems, PanOptix Pro and a fast-ramping dry-eye franchise drove 7% constant-currency growth in the second quarter — even as Alcon took a $402m charge to discontinue its PowerVision accommodating lens programs and struck a light-adjustable IOL collaboration with RxSight.
Medtech Insight - August 12, 2026
J&J Bets on Outpatient Ablation Boom With ACCESS GPO Electrophysiology Deal
J&J has bundled its full electrophysiology technology stack into a single GPO agreement with ACCESS, giving physician-led ambulatory surgery centers a coordinated route to mapping, imaging and dual-energy ablation as outpatient cardiac care volume grows.
Medtech Insight - August 12, 2026
J&J has bundled its full electrophysiology technology stack into a single GPO agreement with ACCESS, giving physician-led ambulatory surgery centers a coordinated route to mapping, imaging and dual-energy ablation as outpatient cardiac care volume grows.
Medtech Insight - August 12, 2026
Hikma Delivers More Profit From Modest Sales Growth
The success detailed in the UK-based Hikma's H1 earnings report acts as a lesson for industry with a notably impressive operating leverage despite pricing erosions and other market challenges.
Generics Bulletin - August 12, 2026
The success detailed in the UK-based Hikma's H1 earnings report acts as a lesson for industry with a notably impressive operating leverage despite pricing erosions and other market challenges.
Generics Bulletin - August 12, 2026
Amneal’s $1bn Kashiv Acquisition Crosses The Finish Line
Amneal has completed its acquisition of Kashiv BioSciences, creating what it calls one of the industry's few fully integrated biosimilar platforms.
Generics Bulletin - August 12, 2026
Amneal has completed its acquisition of Kashiv BioSciences, creating what it calls one of the industry's few fully integrated biosimilar platforms.
Generics Bulletin - August 12, 2026
Aurobindo Claims 5-7 Year Headstart With A1 Biochem, Lannett Acquisitions
The acquisition of US-based Lannett and India’s A1 Biochem, that has a US lab, have helped Aurobindo Pharma leapfrog onshoring and R&D capability scale-ups by five to seven years, giving it the confidence to handle mandatory US onshoring if required.
Generics Bulletin - August 12, 2026
The acquisition of US-based Lannett and India’s A1 Biochem, that has a US lab, have helped Aurobindo Pharma leapfrog onshoring and R&D capability scale-ups by five to seven years, giving it the confidence to handle mandatory US onshoring if required.
Generics Bulletin - August 12, 2026
Towa’s Core Generics And European Growth Outrun Fresh Sunsho Weakness
Japanese generics player Towa has kept its full-year guidance intact as higher domestic volumes and European growth offset further deterioration at its impaired Sunsho business.
Generics Bulletin - August 12, 2026
Japanese generics player Towa has kept its full-year guidance intact as higher domestic volumes and European growth offset further deterioration at its impaired Sunsho business.
Generics Bulletin - August 12, 2026
Samsung Bioepis Breaks Korean Ground For Keytruda
Samsung Bioepis has filed SB27 for approval in South Korea across 16 Keytruda indications, backed by successful Phase I and III trials, as rival pembrolizumab developers increasingly streamline their clinical programs.
Generics Bulletin - August 12, 2026
Samsung Bioepis has filed SB27 for approval in South Korea across 16 Keytruda indications, backed by successful Phase I and III trials, as rival pembrolizumab developers increasingly streamline their clinical programs.
Generics Bulletin - August 12, 2026
Eric Green’s Vision For Trace Neuroscience
Eric Green, CEO and co-founder of Trace Neuroscience, shared the progress his company has made — and the potential he sees — since its founding in 2024.
In Vivo - August 12, 2026
Eric Green, CEO and co-founder of Trace Neuroscience, shared the progress his company has made — and the potential he sees — since its founding in 2024.
In Vivo - August 12, 2026
EU’s AI Act Climbdown Raises Stakes For MDR Revisions
MDR/IVDR simplifications are finally on the table, but differing stakeholder views and AI Act walkbacks cast doubt on their future.
Medtech Insight - August 12, 2026
MDR/IVDR simplifications are finally on the table, but differing stakeholder views and AI Act walkbacks cast doubt on their future.
Medtech Insight - August 12, 2026
Sanofi’s Bilingual Scientist: A Workforce Rebuilt Around AI
The company says it has cut research cycle times in half and wants to double its molecule output. Its new CEO is cutting late-stage assets and raising the bar for what advances – which makes the workforce it is building the bet that must pay off.
In Vivo - August 12, 2026
The company says it has cut research cycle times in half and wants to double its molecule output. Its new CEO is cutting late-stage assets and raising the bar for what advances – which makes the workforce it is building the bet that must pay off.
In Vivo - August 12, 2026
Asia-Pacific’s Medtech Pivot: From Factory Floor To Innovation Engine
A new Bain report says Asia-Pacific has shifted from medtech's factory floor to a genuine innovation source — 36% of global device research, two-thirds of patent filings, 30% of FDA 510(k) clearances. But a <5% share of FDA De Novo authorizations shows how far the region still has to climb.
Medtech Insight - August 12, 2026
A new Bain report says Asia-Pacific has shifted from medtech's factory floor to a genuine innovation source — 36% of global device research, two-thirds of patent filings, 30% of FDA 510(k) clearances. But a <5% share of FDA De Novo authorizations shows how far the region still has to climb.
Medtech Insight - August 12, 2026
Axing Self-Affirmed GRAS Pathway Without Notification Spurs Resource, Authority Questions
Demand on FDA resources and one-year deadline following effective date for notifications for ingredients already available self-GRAS but not notified could be more than FDA bargains for. Proposed rule also could order more than FDA has authority to do.
HBW Insight - August 12, 2026
Demand on FDA resources and one-year deadline following effective date for notifications for ingredients already available self-GRAS but not notified could be more than FDA bargains for. Proposed rule also could order more than FDA has authority to do.
HBW Insight - August 12, 2026
Finance Watch: A Pair Of Startups Launch With High-Profile Execs At The Helm
Private Company Edition: K2 Therapeutics emerges with $50m in seed funding and CEO Ying Huang, who recently vacated the CEO post at Legend Biotech. Boulevard Bio came out of stealth with $65m and former Sanofi CSO Frank Nestle as a co-founder and board member.
Scrip - August 12, 2026
Private Company Edition: K2 Therapeutics emerges with $50m in seed funding and CEO Ying Huang, who recently vacated the CEO post at Legend Biotech. Boulevard Bio came out of stealth with $65m and former Sanofi CSO Frank Nestle as a co-founder and board member.
Scrip - August 12, 2026
In Brief: Lilly Goes Into Battle To Defend Retatrutide From Illegal Sellers
The Indianapolis drugmaker filed six lawsuits against companies selling versions of the drug and asked the service providers they depend on to step up as well.
Scrip - August 12, 2026
The Indianapolis drugmaker filed six lawsuits against companies selling versions of the drug and asked the service providers they depend on to step up as well.
Scrip - August 12, 2026
Definium Riding High On Psychedelic Success In GAD
The company reported positive Phase III data for DT120 in generalized anxiety disorder, an area that has not seen a new drug approved in nearly 20 years.
Scrip - August 12, 2026
The company reported positive Phase III data for DT120 in generalized anxiety disorder, an area that has not seen a new drug approved in nearly 20 years.
Scrip - August 12, 2026
In Brief: US Preferred For First-In-Human Trials, But Obstacles Send Sponsors Abroad
A new survey by MassBio and BCAI found that US FDA practices are making countries like China and Australia more attractive, though the FDA has already begun to respond.
Scrip - August 12, 2026
A new survey by MassBio and BCAI found that US FDA practices are making countries like China and Australia more attractive, though the FDA has already begun to respond.
Scrip - August 12, 2026
ITM Setback Highlights Challenges Of Making Radiopharmaceuticals
The German firm has received a complete response letter from the US FDA for its GEP-NET product due to manufacturing issues but remains confident of approval.
Scrip - August 12, 2026
The German firm has received a complete response letter from the US FDA for its GEP-NET product due to manufacturing issues but remains confident of approval.
Scrip - August 12, 2026
Speed to Scale: How India’s Pharma Market Is Minting Billion-Rupee Brands
More pharma brands in India ranging from in-licensed Chinese cancer therapies to cough and cold medications are crossing the INR100 crore sales threshold, with some doing so faster than ever before. Experts discuss the trend and also what Mounjaro's extraordinary market entry reveals.
Scrip - August 12, 2026
More pharma brands in India ranging from in-licensed Chinese cancer therapies to cough and cold medications are crossing the INR100 crore sales threshold, with some doing so faster than ever before. Experts discuss the trend and also what Mounjaro's extraordinary market entry reveals.
Scrip - August 12, 2026
Former SpineFrontier CFO Sentenced To Four Months In Surgeon Kickback Scheme
The former CFO of spinal implant firm SpineFrontier Inc. will serve four months in prison for his role in paying sham consulting fees to surgeons who agreed to use the company’s products.
Medtech Insight - August 12, 2026
The former CFO of spinal implant firm SpineFrontier Inc. will serve four months in prison for his role in paying sham consulting fees to surgeons who agreed to use the company’s products.
Medtech Insight - August 12, 2026
Four Serious Injuries Linked to Class I Recall Of Hamilton Medical Ventilator Circuit Sets
Hamilton Medical is recalling certain coaxial breathing circuit sets after identifying a valve defect that can cause inadequate ventilation and oxygen desaturation. The Class I recall is associated with four serious injuries but no deaths and follows an early alert the agency posted in June.
Medtech Insight - August 12, 2026
Hamilton Medical is recalling certain coaxial breathing circuit sets after identifying a valve defect that can cause inadequate ventilation and oxygen desaturation. The Class I recall is associated with four serious injuries but no deaths and follows an early alert the agency posted in June.
Medtech Insight - August 12, 2026
Alcon’s New-Product Wave Carries Q2 As It Walks Away From Accommodating IOL Bet
UNITY surgical systems, PanOptix Pro and a fast-ramping dry-eye franchise drove 7% constant-currency growth in the second quarter — even as Alcon took a $402m charge to discontinue its PowerVision accommodating lens programs and struck a light-adjustable IOL collaboration with RxSight.
Medtech Insight - August 12, 2026
UNITY surgical systems, PanOptix Pro and a fast-ramping dry-eye franchise drove 7% constant-currency growth in the second quarter — even as Alcon took a $402m charge to discontinue its PowerVision accommodating lens programs and struck a light-adjustable IOL collaboration with RxSight.
Medtech Insight - August 12, 2026
J&J Bets on Outpatient Ablation Boom With ACCESS GPO Electrophysiology Deal
J&J has bundled its full electrophysiology technology stack into a single GPO agreement with ACCESS, giving physician-led ambulatory surgery centers a coordinated route to mapping, imaging and dual-energy ablation as outpatient cardiac care volume grows.
Medtech Insight - August 12, 2026
J&J has bundled its full electrophysiology technology stack into a single GPO agreement with ACCESS, giving physician-led ambulatory surgery centers a coordinated route to mapping, imaging and dual-energy ablation as outpatient cardiac care volume grows.
Medtech Insight - August 12, 2026
EU’s AI Act Climbdown Raises Stakes For MDR Revisions
MDR/IVDR simplifications are finally on the table, but differing stakeholder views and AI Act walkbacks cast doubt on their future.
Medtech Insight - August 12, 2026
MDR/IVDR simplifications are finally on the table, but differing stakeholder views and AI Act walkbacks cast doubt on their future.
Medtech Insight - August 12, 2026
Asia-Pacific’s Medtech Pivot: From Factory Floor To Innovation Engine
A new Bain report says Asia-Pacific has shifted from medtech's factory floor to a genuine innovation source — 36% of global device research, two-thirds of patent filings, 30% of FDA 510(k) clearances. But a <5% share of FDA De Novo authorizations shows how far the region still has to climb.
Medtech Insight - August 12, 2026
A new Bain report says Asia-Pacific has shifted from medtech's factory floor to a genuine innovation source — 36% of global device research, two-thirds of patent filings, 30% of FDA 510(k) clearances. But a <5% share of FDA De Novo authorizations shows how far the region still has to climb.
Medtech Insight - August 12, 2026
Methyl-Life Founder Turned From Health Crisis To Personalized Nutrients Targeting Genetic Factors
Jamie Hope discovered her chronic illness with symptoms including crippling fatigue, debilitating headaches, extreme muscle stiffness and pain, belly pain and low mood, was linked to genetic factors requiring specialized nutrients.
HBW Insight - August 12, 2026
Jamie Hope discovered her chronic illness with symptoms including crippling fatigue, debilitating headaches, extreme muscle stiffness and pain, belly pain and low mood, was linked to genetic factors requiring specialized nutrients.
HBW Insight - August 12, 2026
Reckitt’s Mucinex 12HR Cold & Fever Approved On Additional Evidence Supporting Naproxen Dosing
Reckitt launching Mucinex 12HR Cold & Fever Multi-Symptom following FDA approval in December 2025 and after it responded to complete response letter with additional evidence supporting combining naproxen with guaifenesin and dextromethorphan used in Mucinex DM.
HBW Insight - August 12, 2026
Reckitt launching Mucinex 12HR Cold & Fever Multi-Symptom following FDA approval in December 2025 and after it responded to complete response letter with additional evidence supporting combining naproxen with guaifenesin and dextromethorphan used in Mucinex DM.
HBW Insight - August 12, 2026
Axing Self-Affirmed GRAS Pathway Without Notification Spurs Resource, Authority Questions
Demand on FDA resources and one-year deadline following effective date for notifications for ingredients already available self-GRAS but not notified could be more than FDA bargains for. Proposed rule also could order more than FDA has authority to do.
HBW Insight - August 12, 2026
Demand on FDA resources and one-year deadline following effective date for notifications for ingredients already available self-GRAS but not notified could be more than FDA bargains for. Proposed rule also could order more than FDA has authority to do.
HBW Insight - August 12, 2026
Hikma Delivers More Profit From Modest Sales Growth
The success detailed in the UK-based Hikma's H1 earnings report acts as a lesson for industry with a notably impressive operating leverage despite pricing erosions and other market challenges.
Generics Bulletin - August 12, 2026
The success detailed in the UK-based Hikma's H1 earnings report acts as a lesson for industry with a notably impressive operating leverage despite pricing erosions and other market challenges.
Generics Bulletin - August 12, 2026
Amneal’s $1bn Kashiv Acquisition Crosses The Finish Line
Amneal has completed its acquisition of Kashiv BioSciences, creating what it calls one of the industry's few fully integrated biosimilar platforms.
Generics Bulletin - August 12, 2026
Amneal has completed its acquisition of Kashiv BioSciences, creating what it calls one of the industry's few fully integrated biosimilar platforms.
Generics Bulletin - August 12, 2026
Aurobindo Claims 5-7 Year Headstart With A1 Biochem, Lannett Acquisitions
The acquisition of US-based Lannett and India’s A1 Biochem, that has a US lab, have helped Aurobindo Pharma leapfrog onshoring and R&D capability scale-ups by five to seven years, giving it the confidence to handle mandatory US onshoring if required.
Generics Bulletin - August 12, 2026
The acquisition of US-based Lannett and India’s A1 Biochem, that has a US lab, have helped Aurobindo Pharma leapfrog onshoring and R&D capability scale-ups by five to seven years, giving it the confidence to handle mandatory US onshoring if required.
Generics Bulletin - August 12, 2026
Towa’s Core Generics And European Growth Outrun Fresh Sunsho Weakness
Japanese generics player Towa has kept its full-year guidance intact as higher domestic volumes and European growth offset further deterioration at its impaired Sunsho business.
Generics Bulletin - August 12, 2026
Japanese generics player Towa has kept its full-year guidance intact as higher domestic volumes and European growth offset further deterioration at its impaired Sunsho business.
Generics Bulletin - August 12, 2026
Samsung Bioepis Breaks Korean Ground For Keytruda
Samsung Bioepis has filed SB27 for approval in South Korea across 16 Keytruda indications, backed by successful Phase I and III trials, as rival pembrolizumab developers increasingly streamline their clinical programs.
Generics Bulletin - August 12, 2026
Samsung Bioepis has filed SB27 for approval in South Korea across 16 Keytruda indications, backed by successful Phase I and III trials, as rival pembrolizumab developers increasingly streamline their clinical programs.
Generics Bulletin - August 12, 2026
Eric Green’s Vision For Trace Neuroscience
Eric Green, CEO and co-founder of Trace Neuroscience, shared the progress his company has made — and the potential he sees — since its founding in 2024.
In Vivo - August 12, 2026
Eric Green, CEO and co-founder of Trace Neuroscience, shared the progress his company has made — and the potential he sees — since its founding in 2024.
In Vivo - August 12, 2026
Sanofi’s Bilingual Scientist: A Workforce Rebuilt Around AI
The company says it has cut research cycle times in half and wants to double its molecule output. Its new CEO is cutting late-stage assets and raising the bar for what advances – which makes the workforce it is building the bet that must pay off.
In Vivo - August 12, 2026
The company says it has cut research cycle times in half and wants to double its molecule output. Its new CEO is cutting late-stage assets and raising the bar for what advances – which makes the workforce it is building the bet that must pay off.
In Vivo - August 12, 2026